After a 10-day course of treatment, melanomas were collected and analyzed by flow cytometry to confirm that the NNC+PPMP therapy decreased the abundance of CD36+ drug-tolerant cells and reduced AGPS expression (Figure 9, D and E). The gene discussed is AGPS; the disease is melanoma.